secwatch.observer — SEC 8-K summary
======================================

Issuer:     Organon & Co. (OGN)
CIK:        0001821825
Form:       8-K
Filed at:   2025-10-27T23:59:59+00:00
Accession:  0001104659-25-102324
Event type: leadership
Sentiment:  negative
Materiality: 0.90
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Organon CEO resigns after probe finds improper Nexplanon wholesaler sales; Morrissey named interim CEO
--------------------------------------------------------------------------------

- Kevin Ali resigned as CEO and Board member; no severance or equity retirement benefits.
- Audit Committee investigation found wholesalers asked to buy excess Nexplanon in 7 quarters; sales <1% of annual revenue but helped meet guidance.
- Joseph Morrissey appointed Interim CEO; salary raised to $1M, bonus target 100%, LTI target $4M, one-time RSU grant of $1M.
- Carrie Cox named Executive Chair; Robert Essner Lead Independent Director; Helene Gayle chairs Talent Committee.
- No restatement of prior financials; 2024 internal control opinion withdrawn; Head of US Commercial & Government Affairs terminated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1821825/000110465925102324/0001104659-25-102324-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1821825/000110465925102324/tm2529513d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-102324

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer